NuPathe , Nasdaq: PATH.XX
Specialty pharma seeking approval for Zelrix, a patch for migraine treatment.
Industry: Health Care
First Day Return: -3.9%
Industry: Health Care
PATH.XX
Specialty pharma seeking approval for Zelrix, a patch for migraine treatment.
| IPO Data | |
|---|---|
| IPO File Date | 05/14/2010 |
| Offer Price | $10.00 |
| Price Range $10.00 - $10.00 | |
| Offer Shares (mm) | 5.0 |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 08/05/2010 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $50 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Conshohocken, PA, United States |
| Founded | 2005 |
| Employees at IPO | 22 |
| Website www.nupathe.com | |
IPO News for NuPathe
NuPathe (PATH.XX) Performance
